MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
39.99
+1.01
+2.59%
After Hours: 40.77 +0.78 +1.95% 19:19 12/31 EST
OPEN
39.00
PREV CLOSE
38.98
HIGH
41.49
LOW
38.71
VOLUME
17.46K
TURNOVER
--
52 WEEK HIGH
41.49
52 WEEK LOW
13.15
MARKET CAP
157.49M
P/E (TTM)
-12.0358
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VTVT last week (1222-1226)?
Weekly Report · 12/29/2025 09:02
vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know
NASDAQ · 12/24/2025 17:00
Weekly Report: what happened at VTVT last week (1215-1219)?
Weekly Report · 12/22/2025 09:02
vTv Therapeutics Lowers Stockholder Meeting Quorum to 33.4%
Reuters · 12/19/2025 22:11
vTv Therapeutics Price Target Raised to $47.00/Share From $36.00 by HC Wainwright & Co.
Dow Jones · 12/19/2025 15:30
vTv Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/19/2025 15:30
HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Raises Price Target to $47
Benzinga · 12/19/2025 15:20
VTV THERAPEUTICS INC <VTVT.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $47 FROM $36
Reuters · 12/19/2025 13:21
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.